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SHORT COMMUNICATION
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Meta-iodobenzylguanidine (MIBG) is an analogue of nor-
adrenalin which concentrates in adrenergic vesicles. Studies
performed with an iodine-131 radiolabelled form (1311-
MIBG) have shown that it can be used as an imaging agent
for the adrenal medulla (Fischer et al., 1984) and its neo-
plasms (phaeochromocytoma and neuroblastoma) (Hoefnagel
et al., 1987; Kimmig et al., 1984). 1311-MIBG has also been
shown to localise in paraganglioma, another tumour arising
from the sympathetic nervous system (Pease & Polak, 1978),
and in medullary carcinoma of the thyroid (Shapiro et al.,
1985). These tumours show a common APUD (amine pre-
cursor uptake and decarboxylation) mechanism (Sisson et
al., 1981). Carcinoid tumours also possess a number of
APUD properties, including in particular neurosecretory
(dense core) granules and the ability to produce a variety of
biogenic amines. Preliminary studies have suggested that
carcinoid tumours may also take up '311-MIBG (Sisson et
al., 1984; Smit et al., 1984).
If carcinoid tumours were shown to take up this radio-
pharmaceutical with sufficient concentration then it might be
possible to achieve therapeutic doses of 131I-MIBG, a tech-
nique successfully employed with malignant phaeochromo-
cytoma (Sone et al., 1985).
We describe a study to investigate further the uptake of
1311-MIBG for diagnostic imaging in II patients with con-
firmed metastatic carcinoid tumours.
Eleven patients known to have metastatic carcinoid
tumours were studied. In 5 patients secondary deposits were
histologically confirmed as carcinoid. The remaining 6
patients had metastatic tumours diagnosed by CT scanning
or ultrasound and elevated urinary 5 hydroxyindoleacetic
acid (5HIAA) levels, the original primary tumour had been
diagnosed histologically. Ten of the II patients had abdomi-
nal CT scan or ultrasound to document metastases. An
NMR scan was performed in one patient (10). Bone scans
were only performed in patients with bone pain. Patient
details are shown in Table I.
The patients received 0.3ml of Lugol's iodine 3 times a
day for 3 days prior to and 3 days after administration of
131I-MIBG to prevent thyroid uptake of the radioiodine.
131I-MIBG (20-40mBq) was injected intravenously.
Imaging was performed at 24 and 48h following injection
for all patients, and at 72h in 6 patients, using a Siemen's
ZLC75 Gamma camera.
A medium energy collimator was used with the peak set at
350KeV and a window of 15%. Images were acquired over
600 seconds. Planar anterior and posterior views of the chest
and abdomen were taken with selective views of clinically
involved areas.
Table I Patient characteristics.
Age
Sex
No. ofsites ofdisease
5HIAA levels
Sites ofprimary tumour
41-72 (Median 60)
M: 5 F: 6
1-3 (Median 1)
115-1,198 (Median 845)pmol 24h-
Ileum 4, Ovary 1, Lung 2
Unknown 4
Correspondence: I.E. Smith.
Received 20 March 1988; and in revised form, 8 July 1988.
Uptake at tumour sites was compared with normal uptake
both in the liver and the myocardium.
The levels of 1311-MIBG in the areas involved by carci-
noid tumour in relation to the myocardial and liver uptakes
are summarised in Table II together with the sites of disease,
symptoms experienced and urinary 5HIAA levels for indi-
vidual patients.
In 8 (73%) patients unequivocal abnormal uptake was
seen. One patient (8) had abnormal uptake in a single area
within the liver, whereas CT scan showed multiple meta-
stases. One patient (2) demonstrated a mixture of 'hot' and
'cold' areas in the liver. In 3 patients no abnormal uptake
was seen. No sites of disease were identified on '31I-MIBG
scintigraphy that were not also detectable by other tests. One
patient (5) with a negative 131I-MIBG scintigram was the
only patient in our group to have bone metastases (histo-
logically proven) and he also suffered no 'carcinoid' symp-
toms. A 99Tcm methylenediphosphonate bone scintigram
showed multiple areas of increased uptake, and this appear-
ance was shown to be gradually progressing over a 4-year
period. A second patient with a negative '311-MIBG scinti-
gram (11) had only moderately elevated 5HIAA levels and
was asymptomatic. The third had a lung primary with
hepatic metastases, an elevated 5HIAA and marked symp-
toms. The liver metastases were documented by ultrasound
and CT scanning.
We found no correlation between the urinary 5HIAA
levels and 1311-MIBG uptake in the tumours. One patient (6)
had levels only modestly raised at 132,mol 24h- I
(N<75,umol 24 h-1) but an unequivocally positive scinti-
gram and marked symptoms while another patient with
5HIAA levels 5 times this level had a negative scintigram.
We also found no relationship between 'carcinoid symp-
tomatology' and 131I-MIBG uptake. Patient 5 suffered florid
carcinoid symptoms (with elevated urinary 5HIAA levels)
but no uptake of the 1311-MIBG was seen.
We did not observe an increase in uptake of the 131I-
MIBG after 48h and therefore scanning at 72h was discon-
tinued. Compared with other studies we saw low levels of
myocardial activity at 48h (none in 6/11 patients).
Our results confirm that 1311-MIBG is preferentially taken
up by the majority of metastatic carcinoid tumours, with a
73% positive uptake in this study compared with 63% in
Hoefnagel's series (Hoefnagel et al., 1987). However, this
incidence is lower than in malignant phaeochromocytoma
where more than 90% of lesions take up 131I-MIBG (Wie-
land et al., 1981). In keeping with other authors we found no
correlation between urinary 5HIAA and 131I-MIBG uptake.
However, we were unable to confirm the relationship
between carcinoid symptomatology and 1311-MIBG uptake
reported by Hoefnagel et al. (1987).
We were unable to demonstrate preferential uptake of
radiolabelled MIBG in particular sites. Although our only
patient with bony metastases did not show any uptake of
1311-MIBG, Hoefnagel found that 2 of 3 patients with bone
involvement showed abnormal uptake.
In 2 patients the uptake varied from lesion to lesion. The
I311-MIBG scintigram suggested a solitary hepatic meta-
stasis, while the CT scan showed multiple lesions. It is
possible that these appearances represent a mixture of func-
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Table II
Urinary
5HIAA 'Carcinoid' 131I-MIBG Myocardial Confirmatory
Patient N<75pmol24h-1 Sites symptoms uptake uptake tests
1 845 Li,P D Li=3, P=2 0 CT Histo
2 208 Li D Li=3 and 0 0 CT
3 957 Li D, F, B Li=3 I US
4 986 Li Nil Li=3 0 CT Histo
5 658 Li D, F, B No abnormal uptake 0 US Histo
6 132 Li D, F, B Li=3 I CT
7 115 B Nil No abnormal uptake 0 XR Bone scan
CT Histo
8 1,198 Li,S,N D Li=3, S=2, N=0 0 CT US Histo
9 517 Li F Li=3 1 US CT
10 871 Lu, M, N D, F Li=3, M=3a 2 CT NMR Histo
11 177 Li, Lu Nil No abnormal uptake 1 CT Histo
aN obscured by liver.
Sites: Li =Liver N =Nodes Symptoms: F =Flushing
Lu =Lung P =Pelvic mass D=Diarrhoea
B =Bone M =Mesentery B =Bronchospasm
S =Spleen
Uptake grade: 0 No activity
1 Less than normal liver
2 Similar to normal liver
3 Greater than normal liver
tioning and non-functioning lesions, or alternatively poorly
functioning lesions may not be seen due to the low activities
used and the limitations of planar imaging. This variability
of uptake may have implications in future attempts at
therapy.
The preferential uptake of 1311-MIBG by phaeochromo-
cytomas has led to successful attempts at radiotherapeutic
ablation using larger doses of this radiopharmaceutical (Sone
et al., 1985). A small number of patients with carcinoid have
also been treated in this way and although some sympto-
matic improvements have been seen, no tumour regression
has so far been reported (Hoefnagel et al., 1987). Neverthe-
less the frequency of positive uptake suggests that the
therapeutic potential merits further investigation.
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